Literature DB >> 29563333

Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits.

Wen Ding1,2, Keyvan Yousefi1,2, Stefania Goncalves3, Bradley J Goldstein2,3, Alfonso L Sabater4, Amy Kloosterboer5, Portia Ritter5, Guerline Lambert5, Armando J Mendez6, Lina A Shehadeh2,5,7,8.   

Abstract

Alport syndrome is a rare hereditary renal disorder with no etiologic therapy. We found that osteopontin (OPN) is highly expressed in the renal tubules of the Alport mouse and plays a causative pathological role. OPN genetic deletion ameliorated albuminuria, hypertension, tubulointerstitial proliferation, renal apoptosis, and hearing and visual deficits in the Alport mouse. In Alport renal tubules we found extensive cholesterol accumulation and increased protein expression of dynamin-3 (DNM3) and LDL receptor (LDLR) in addition to dysmorphic mitochondria with defective bioenergetics. Increased pathological cholesterol influx was confirmed by a remarkably increased uptake of injected DiI-LDL cholesterol by Alport renal tubules, and by the improved lifespan of the Alport mice when crossed with the Ldlr-/- mice with defective cholesterol influx. Moreover, OPN-deficient Alport mice demonstrated significant reduction of DNM3 and LDLR expression. In human renal epithelial cells, overexpressing DNM3 resulted in elevated LDLR protein expression and defective mitochondrial respiration. Our results suggest a potentially new pathway in Alport pathology where tubular OPN causes DNM3- and LDLR-mediated enhanced cholesterol influx and impaired mitochondrial respiration.

Entities:  

Keywords:  Collagens; Cytokines; Fatty acid oxidation; Metabolism; Nephrology

Mesh:

Substances:

Year:  2018        PMID: 29563333      PMCID: PMC5926939          DOI: 10.1172/jci.insight.94818

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  76 in total

1.  Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse.

Authors:  Kyungmin Hahm; Matvey E Lukashev; Yi Luo; William J Yang; Brian M Dolinski; Paul H Weinreb; Kenneth J Simon; Li Chun Wang; Diane R Leone; Roy R Lobb; Donald J McCrann; Normand E Allaire; Gerald S Horan; Agnes Fogo; Raghu Kalluri; Charles F Shield; Dean Sheppard; Humphrey A Gardner; Shelia M Violette
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 2.  Alport syndrome: clinical update.

Authors:  D C Wester; C L Atkin; M C Gregory
Journal:  J Am Acad Audiol       Date:  1995-01       Impact factor: 1.664

3.  Glomerular lipid deposition and proteinuria in a patient with familial dysbetalipoproteinaemia.

Authors:  K R Balson; J F Niall; J D Best
Journal:  J Intern Med       Date:  1996-09       Impact factor: 8.989

4.  Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis.

Authors:  R Kalluri; C F Shield; P Todd; B G Hudson; E G Neilson
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

Review 5.  Osteopontin: role in cell signaling and cancer progression.

Authors:  Hema Rangaswami; Anuradha Bulbule; Gopal C Kundu
Journal:  Trends Cell Biol       Date:  2006-01-10       Impact factor: 20.808

Review 6.  Expression, roles, receptors, and regulation of osteopontin in the kidney.

Authors:  Y Xie; M Sakatsume; S Nishi; I Narita; M Arakawa; F Gejyo
Journal:  Kidney Int       Date:  2001-11       Impact factor: 10.612

7.  A mutation in the mitochondrial fission gene Dnm1l leads to cardiomyopathy.

Authors:  Houman Ashrafian; Louise Docherty; Vincenzo Leo; Christopher Towlson; Monica Neilan; Violetta Steeples; Craig A Lygate; Tertius Hough; Stuart Townsend; Debbie Williams; Sara Wells; Dominic Norris; Sarah Glyn-Jones; John Land; Ivana Barbaric; Zuzanne Lalanne; Paul Denny; Dorota Szumska; Shoumo Bhattacharya; Julian L Griffin; Iain Hargreaves; Narcis Fernandez-Fuentes; Michael Cheeseman; Hugh Watkins; T Neil Dear
Journal:  PLoS Genet       Date:  2010-06-24       Impact factor: 5.917

8.  Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis.

Authors:  Kathyrn D Rodgers; Velidi Rao; Daniel T Meehan; Nicole Fager; Philip Gotwals; Sarah T Ryan; Victor Koteliansky; Ryoichi Nemori; Dominic Cosgrove
Journal:  Kidney Int       Date:  2003-04       Impact factor: 10.612

9.  Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.

Authors:  Oliver Gross; Bogdan Beirowski; Marie-Louise Koepke; Jeannine Kuck; Michael Reiner; Klaus Addicks; Neil Smyth; Eckhard Schulze-Lohoff; Manfred Weber
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

Review 10.  Mitochondrial dysfunction in the pathophysiology of renal diseases.

Authors:  Ruochen Che; Yanggang Yuan; Songming Huang; Aihua Zhang
Journal:  Am J Physiol Renal Physiol       Date:  2013-12-04
View more
  13 in total

1.  LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring.

Authors:  Portia Ritter; Keyvan Yousefi; Juliana Ramirez; Derek M Dykxhoorn; Armando J Mendez; Lina A Shehadeh
Journal:  J Vis Exp       Date:  2018-11-17       Impact factor: 1.355

Review 2.  Podocyte Lipotoxicity in CKD.

Authors:  Jin-Ju Kim; Sydney S Wilbon; Alessia Fornoni
Journal:  Kidney360       Date:  2021-02-26

3.  Osteopontin Promotes Left Ventricular Diastolic Dysfunction Through a Mitochondrial Pathway.

Authors:  Keyvan Yousefi; Camila I Irion; Lauro M Takeuchi; Wen Ding; Guerline Lambert; Trevor Eisenberg; Sarah Sukkar; Henk L Granzier; Mei Methawasin; Dong I Lee; Virginia S Hahn; David A Kass; Konstantinos E Hatzistergos; Joshua M Hare; Keith A Webster; Lina A Shehadeh
Journal:  J Am Coll Cardiol       Date:  2019-06-04       Impact factor: 24.094

4.  Carvedilol and exercise combination therapy improves systolic but not diastolic function and reduces plasma osteopontin in Col4a3-/- Alport mice.

Authors:  Julian C Dunkley; Camila I Irion; Keyvan Yousefi; Serene A Shehadeh; Guerline Lambert; Krista John-Williams; Keith A Webster; Jeffrey J Goldberger; Lina A Shehadeh
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-03-26       Impact factor: 4.733

5.  Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells.

Authors:  Wen Ding; Keyvan Yousefi; Lina A Shehadeh
Journal:  J Vis Exp       Date:  2018-06-20       Impact factor: 1.355

6.  Osteopontin Expression in Cardiomyocytes Is Increased in Pediatric Patients With Sepsis or Pneumonia.

Authors:  Camila Iansen Irion; Kiera Parrish; Krista John-Williams; Sakir H Gultekin; Lina A Shehadeh
Journal:  Front Physiol       Date:  2018-12-10       Impact factor: 4.566

7.  A preclinical model for phenogroup 3 HFpEF.

Authors:  Keyvan Yousefi; Julian C Dunkley; Lina A Shehadeh
Journal:  Aging (Albany NY)       Date:  2019-07-15       Impact factor: 5.682

8.  Osteopontin and LDLR Are Upregulated in Hearts of Sudden Cardiac Death Victims With Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus.

Authors:  Mausam Patel; Daniela Rodriguez; Keyvan Yousefi; Krista John-Williams; Armando J Mendez; Ronald B Goldberg; Anastasios Lymperopoulos; Leonardo J Tamariz; Jeffrey J Goldberger; Robert J Myerburg; Juhani Junttila; Lina A Shehadeh
Journal:  Front Cardiovasc Med       Date:  2020-11-30

9.  Creation of X-linked Alport syndrome rat model with Col4a5 deficiency.

Authors:  Tomoe Kobayashi; Mayumi Kohno; Masumi Namba; Takayuki Koyano; Takuo Hirose; Masaki Fukushima; Makoto Matsuyama
Journal:  Sci Rep       Date:  2021-10-21       Impact factor: 4.996

Review 10.  Crosstalk Between Lipids and Mitochondria in Diabetic Kidney Disease.

Authors:  G Michelle Ducasa; Alla Mitrofanova; Alessia Fornoni
Journal:  Curr Diab Rep       Date:  2019-11-21       Impact factor: 5.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.